Skip to main content
. 2020 Oct 15;12(10):6908–6920.

Figure 1.

Figure 1

The distinct upregulation of NCK1-AS1 expression in NSCLC patients and its clinical value. A. The Pan-Cancer Analysis of NCK1-AS1 expression based on the TCGA datasets. B. NCK1-AS1 expression was increased in LUAD and LUSC analyzed using GEPIA tool. C, D. Violin Plot for the expression of NCK1-AS1 in LUAD and LUSC tissues with different stages analyzed using GEPIA tool. E. Relative expression of NCK1-AS1 expression in NSCLC specimens (n = 148) and in paired adjacent normal specimens (n = 148). NCK1-AS1 expression was examined by qPCR and normalized to GAPDH expression (shown as 2-ΔCT). F. A high level of NCK1-AS1 was observed in NSCLC specimens with advanced stages in our cohort. G. qPCR detected the expression levels of NCK1-AS1 in 16HBE and five NSCLC cell lines. H. Receiver-operating characteristic (ROC) curves were used to evaluate the performance of NCK1-AS1 to discriminate NSCLC specimens from non-tumor specimens. I. The survival assays of the overall survival and disease-free survival of 475 LUAD patients analyzed using GEPIA tool. J, K. The survival assays of the overall survival and disease-free survival of 482 LUSC patients analyzed using GEPIA tool. L, M. Kaplan-Meier curves of the overall survival and disease-free survival of 148 NSCLC patients. ***P < 0.011, *P < 0.05.